Borthwick Diabetes Research Centre, Lister Hospital (East and North Hertfordshire NHS Trust), Stevenage, UK.
Department of Biomedical Sciences, Swansea University Medical School, Swansea, UK.
Endocrinol Metab (Seoul). 2023 Feb;38(1):25-33. doi: 10.3803/EnM.2022.1642. Epub 2023 Feb 6.
The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations by professional guidelines suggest that GLP1 receptor agonists should replace more traditional treatment options such as sulfonylureas and dipeptidyl-peptidase 4 (DPP4) inhibitors. Furthermore, their benefits in reducing cardiovascular events in people with type 2 diabetes beyond improvements in glycaemic control has led to numerous clinical trials seeking to translate this benefit beyond type 2 diabetes. Following early trial results their therapeutic benefit is currently being tested in other conditions including fatty liver disease, kidney disease, and Alzheimer's disease.
肠促胰岛素激素胰高血糖素样肽 1（GLP1）对 2 型糖尿病和/或肥胖患者的治疗益处已得到充分证实。来自 2 型糖尿病患者头对头比较有效性研究的证据基础，以及专业指南的建议表明，GLP1 受体激动剂应该替代更传统的治疗选择，如磺酰脲类药物和二肽基肽酶 4（DPP4）抑制剂。此外，它们在改善 2 型糖尿病患者血糖控制的基础上，降低心血管事件的益处，促使许多临床试验试图将这种益处扩展到 2 型糖尿病以外的领域。在早期试验结果之后，它们的治疗益处目前正在其他疾病中进行测试，包括脂肪肝疾病、肾脏疾病和阿尔茨海默病。
